Re-instatement to Official Quotation Imminent
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
14 May 2024
Re-instatement to Official Quotation Imminent
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through
the early detecfion of cancer, is pleased to announce that IBX will be re-instated to official quotafion
once a new Australian Director has been appointed.
Following the release of IBX’s 2023 Annual Report, the ASX has indicated that it will re-instate IBX to
official quotafion once it is in compliance with s201A(2) of the Corporafions Act, i.e. the requirement
for a public company to have at least 3 directors, 2 of whom must reside in Australia. IBX is currently
considering the appointment of an appropriate Australian resident Director.
ENDS
About Imagion Biosystems
Imagion Biosystems is an ASX-listed company dedicated to developing innovafive medical imaging
technologies for various cancer types. Imagion Biosystems is advancing clinical development of its
MagSense® plafform technology to revolufionize cancer diagnosis, introducing molecular imaging to
MRI. The Company’s lead program has demonstrated its innovafive technology embodied in
MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in pafients diagnosed with
HER2+ breast cancer. Imagion Biosystems’ MagSense® pipeline includes prostate cancer, ovarian
cancer, pancreafic cancer, and brain cancer programs.
For more informafion, visit hftps://imagionbiosystems.com/investor-hub/
Authorisafion & Addifional informafion
This announcement was authorised by the Board of Imagion Biosystems Limited.
Share your feedback
Discover